Center on Health Equity & Access

MA grocery card use was associated with modest increases in wellness, primary care, and specialist visits among dual-eligible beneficiaries, says Jennifer L. Kowalski, MS.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

New GLP-1 pills challenge injections as competition, and discussions of possible Medicare coverage could push prices down.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Phase 2 trial finds 5-day preoperative RT in high-risk STS shows comparable wound complication rates and acceptable toxicity.

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health access and outcomes.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

The number of brick and mortar abortion clinics in the US fell between 2024 and 2025, with notable closures even in states considered key access points.

Learn what sickle cell disease is, who it affects most, today’s treatment options, and how cost and inequities limit access.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Advances in sickle cell therapies, including gene editing, offer hope—but racial disparities, cost, and access barriers remain major challenges.

Oral GLP-1 costs, insurance gaps, and formulary switches reshape drug pricing and access—learn how to navigate coverage.

Providing monthly produce prescriptions to patients with diabetes at risk for food insecurity did not significantly improve cardiometabolic parameters.

Jordan Karlitz, MD, highlights racial, ethnic, and socioeconomic disparities in rising CRC mortality rates among younger adults, driven by gaps in screening and awareness.

NHANES data reveal a US sleep crisis: Chronic sleep deprivation gaps tied to education, BMI, and food security, via Blinder-Oaxaca decomposition.

New reports reveal rising insurance costs, senior drug savings, and cancer care inequities, showing how policy and partnerships shape health outcomes.

Sarah M. Lima, PhD, MPH, on how historical redlining continues to shape breast cancer survival disparities through treatment access and innovation.

Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.

Study finds breast cancer survival gaps tied to historical redlining narrowed over time, though newer therapies may be widening disparities again.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.